Solid Biosciences (SLDB) Liabilities and Shareholders Equity (2017 - 2024)
Solid Biosciences (SLDB) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $211.8 million as the latest value for Q3 2024.
- Quarterly Liabilities and Shareholders Equity rose 14.67% to $211.8 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $691.5 million through Dec 2024, down 11.8% year-over-year, with the annual reading at $164.9 million for FY2023, 36.62% down from the prior year.
- Liabilities and Shareholders Equity hit $211.8 million in Q3 2024 for Solid Biosciences, down from $231.0 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $285.3 million in Q1 2021 to a low of $40.5 million in Q3 2020.
- Historically, Liabilities and Shareholders Equity has averaged $195.4 million across 5 years, with a median of $208.5 million in 2022.
- Biggest five-year swings in Liabilities and Shareholders Equity: tumbled 69.05% in 2020 and later surged 514.51% in 2021.
- Year by year, Liabilities and Shareholders Equity stood at $171.2 million in 2020, then skyrocketed by 35.76% to $232.4 million in 2021, then grew by 11.99% to $260.3 million in 2022, then tumbled by 36.62% to $164.9 million in 2023, then grew by 28.43% to $211.8 million in 2024.
- Business Quant data shows Liabilities and Shareholders Equity for SLDB at $211.8 million in Q3 2024, $231.0 million in Q2 2024, and $248.7 million in Q1 2024.